ArticleProstate cancer and prostatic diseases2021

MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer.

Patrick McCoy et al.PubMed ↗Publisher ↗

No numbers read from the abstract.